Ibrutinib for the treatment of Waldenström macroglobulinemia

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Waldenström macroglobulinemia (WM) is a B-cell non-Hodgkin lymphoma (NHL) characterized by IgM monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Until recently, there was no drug specifically approved for WM by the US FDA, leading to wide variations in therapeutic strategies across the globe. Ibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, is the first drug approved specifically for WM by the FDA after a clinical trial showed impressive response in previously treated WM. Ibrutinib is a non-stem cell toxic and non-neurotoxic option and suitable for long-Term oral maintenance therapy, with the potential of improving survival in WM. With identification of novel genetic mutations impacting response to ibrutinib, it would be possible to individualize therapy based on MYD88 and CXCR4 genotypes. However, long-Term safety and efficacy data are required, and cost-effectiveness needs to be addressed before ibrutinib can gain widespread acceptance for front-line therapy of WM.

Original languageEnglish (US)
Pages (from-to)569-579
Number of pages11
JournalExpert Review of Hematology
Volume8
Issue number5
DOIs
StatePublished - Sep 3 2015

    Fingerprint

Keywords

  • bruton tyrosine kinase
  • ibrutinib
  • immunoglobin M
  • lymphoplasmacytic lymphoma
  • Waldenström macroglobulinemia

ASJC Scopus subject areas

  • Hematology

Cite this